smallcel
lung
cancer
sclc
lung
cancer
histolog
subtyp
unusu
favor
respons
cytotox
chemotherapi
lifethreaten
manifest
present
rare
report
import
clinic
concern
report
case
man
present
rapidonset
refractori
sever
thrombocytopenia
develop
massiv
hemoptysi
death
respiratori
failur
case
provid
clinician
refer
unusu
present
carri
clinic
implic
manag
sclc
patient
smallcel
lung
cancer
sclc
repres
lung
cancer
sclc
differ
nonsmallcel
lung
cancer
rapid
tumor
doubl
time
high
growth
fraction
earli
develop
widespread
metastasi
better
respons
platinum
doublet
chemotherapi
thu
chemotherapi
treatment
mainstay
even
poor
eastern
cooper
oncolog
group
ecog
perform
statu
bone
marrow
involv
paraneoplast
syndrom
common
patient
sclc
hematolog
abnorm
anemia
leukopenia
thrombocytopenia
report
occasion
accompani
bone
marrow
metastasi
paraneoplast
phenomenon
howev
complic
fatal
hemorrhag
rare
report
clinic
present
make
diagnosi
treatment
difficult
herein
report
sclc
patient
present
rapidonset
refractori
sever
thrombocytopenia
develop
fatal
pulmonari
hemorrhag
man
visit
outpati
clinic
complain
cough
dyspnea
borg
scale
current
smoker
packyear
deni
histori
take
medic
ill
includ
cardiovascular
allerg
rheumatolog
respiratori
diseas
complet
blood
count
reveal
valu
within
normal
rang
except
lower
valu
platelet
count
increas
hazi
lower
lobe
right
lung
note
chest
radiographi
return
day
admit
bloodting
sputum
aggrav
dyspnea
borg
scale
ecog
perform
statu
two
afebril
arteri
blood
ga
studi
reveal
ph
paco
mmhg
pao
mmhg
hco
mmoll
spo
room
air
complet
blood
count
result
follow
leukocyt
neutrophil
lymphocyt
monocyt
eosinophil
basophil
hemoglobin
gdl
hematocrit
platelet
serum
lactat
dehydrogenas
level
iul
creactiv
protein
mgdl
hepat
renal
function
test
within
normal
rang
prothrombin
time
activ
partial
thromboplastin
time
ddimer
within
normal
rang
well
cm
size
mass
lower
lobe
right
lung
multipl
lymphadenopathi
mediastin
right
supraclavicular
area
note
chest
ct
scan
fig
peripher
blood
smear
reveal
leukoerythroblastosi
nucleat
erythrocyt
left
shift
neutrophil
antiplatelet
antibodi
antineutrophil
cytoplasm
antibodi
neg
antinuclear
antibodi
within
pulmonari
hemorrhag
sclc
present
normal
rang
risk
bleed
due
sever
thrombocytopenia
bronchoscop
examin
feasibl
postpon
bone
marrow
examin
perform
patient
unabl
maintain
prone
posit
due
dyspnea
platelet
concentr
pack
red
blood
cell
start
given
daili
dexamethason
mg
intraven
administ
four
day
howev
platelet
count
remain
stationari
fig
fifth
day
admiss
cytolog
examin
sputum
yield
diagnosi
sclc
metastat
lesion
observ
brain
mri
bone
scintigraphi
seventh
day
massiv
hemoptysi
ml
per
day
abruptli
occur
dyspnea
rapidli
aggrav
borg
scale
chest
ct
scan
reveal
diffus
ground
glass
opac
consolid
lung
field
tranexam
acid
empir
broadspectrum
antibiot
includ
piperacillintazobactam
levofloxacin
initi
intraven
sputum
gram
stain
cultur
bacteria
fungu
reveal
organ
sputum
cultur
adenoviru
parainfluenza
viru
rhinoviru
respiratori
syncyti
viru
metapneumoviru
coronaviru
bocaviru
enteroviru
neg
antibodi
studi
mycoplasma
pneumonia
rickettsia
neg
antigen
studi
streptococcu
pneumonia
arteri
blood
ga
studi
show
ph
paco
mmhg
pao
mmhg
hco
mmoll
spo
oxygen
suppli
via
reservoir
mask
flow
rate
tenth
day
intub
ventil
mechan
rapidli
deterior
die
respiratori
failur
twelfth
day
famili
want
postmortem
examin
physician
recommend
research
relat
human
use
compli
relev
nation
regul
institut
polici
accord
tenet
helsinki
declar
approv
author
institut
review
board
equival
committe
inform
consent
written
inform
consent
obtain
patient
public
manuscript
accompani
imag
knowledg
first
report
describ
sclc
patient
present
fatal
pulmonari
hemorrhag
due
refractori
thrombocytopenia
sclc
aggress
histolog
subtyp
lung
cancer
howev
favor
respons
expect
patient
extensivestag
diseas
system
chemotherapi
given
lifethreaten
manifest
rare
present
sclc
patient
manifest
appear
present
case
rapidonset
unusu
present
may
delay
diagnosi
hesit
decid
treatment
affect
surviv
advers
therefor
prompt
diagnosi
treatment
critic
issu
hematolog
abnorm
includ
anemia
leukopenia
thrombocytopenia
commonli
observ
due
toxic
anticanc
therapi
howev
hematolog
abnorm
result
bone
marrow
metastasi
paraneoplast
phenomenon
common
result
anticanc
therapi
sever
thrombocytopenia
develop
rapidli
refractori
platelet
transfus
dexamethason
administr
addit
test
antiplatelet
antibodi
antineutrophil
cytoplasm
antibodi
neg
antinuclear
antibodi
within
normal
rang
find
indic
autoimmun
diseas
like
caus
thrombocytopenia
bone
marrow
examin
diagnost
process
evalu
hematolog
abnorm
stage
diseas
howev
rare
chang
stage
bone
marrow
isol
metastat
site
found
fewer
sclc
patient
leukoerythroblast
reaction
peripher
blood
smear
suggest
bone
marrow
metastasi
present
case
although
bronchoscopi
may
consid
local
treatment
massiv
hemoptysi
contraind
patient
sever
thrombocytopenia
diagnost
treatment
plan
determin
take
account
benefit
risk
individu
patient
basi
challeng
everi
possibl
case
clinic
present
current
case
unfamiliar
clinician
rapidonset
life
threaten
howev
prompt
treatment
system
chemotherapi
consid
consid
fit
system
chemotherapi
virtu
younger
age
accept
ecog
perform
statu
absenc
comorbid
diseas
